Merck Stock News

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart

CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.

In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.

Let's be real – the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting i

Big pharma stocks, on balance, have been trading at a discount relative to the broader market for decades. Merck, a tier 1 U.S. pharmaceutical company, has been breaking out of this trend in 2024.

Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We

Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.

In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started.

Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden's efforts to steer the economy through inflation concerns are showing strong results.

Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.

Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.